Abstract
Gastrointestinal complications are common in patients undergoing various forms of cancer treatment, including chemotherapy, radiation therapy, and molecular-targeted therapies. Many of these complications are life-threatening and require prompt diagnosis and treatment. Complications of oncologic therapy can occur in the esophagus (esophagitis, strictures, bacterial, viral and fungal infections), upper gastrointestinal tract (mucositis, bleeding, nausea and vomiting), colon (diarrhea, graft–versus–host disease, colitis and constipation), liver (drug hepatotoxicity and graft–versus–host disease), and pancreas (pancreatitis). Treatment of the different gastrointestinal complications should be tailored to the individual patient and based on the underlying pathophysiology of the complication.
Key Points
-
Gastrointestinal complications of oncologic therapy are common and can affect all organs of the gastrointestinal tract; they are often life-threatening
-
Treatment of gastrointestinal complications of oncologic therapy should be individualized to take into account the patient's status and disease pathophysiology
-
Gastrointestinal complications of oncologic therapy are often multifactorial, involving direct toxicity and secondary events resulting from the immunosuppressive properties of given agents
-
Gastrointestinal complications of therapy must be differentiated from signs and symptoms of underlying disease
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Benson CA et al. (2004) Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Disease Society of America. MMWR Recomm Rep 53: 1–112
McDonald GB et al. (1985) Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 88: 1111–1117
Pappas PG et al. (2004) Guidelines for the treatment of candidiasis. Clin Infect Dis 38: 161–189
Wilcox CM et al. (1997) A randomized, double-blind comparison of Itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 176: 227–232
Ally R et al. (2001) A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33: 1447–1454
Perfect JR et al. (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36: 1122–1131
Villanueva A et al. (2002) A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113: 294–299
De Wet N et al. (2004) A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39: 842–849
Krause DS et al. (2004) A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 39: 770–775
Baehr PH and McDonald GB (1994) Esophageal infections: risk factors, presentation, diagnosis, and treatment. Gastroenterology 106: 509–532
McBane RD and Gross JB Jr (1991) Herpes esophagitis: clinical syndrome, endoscopic appearance, and diagnosis in 23 patients. Gastrointest Endosc 37: 600–603
Reed EC et al. (1990) Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med 112: 505–510
Blanshard C et al. (1995) Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis 172: 622–628
Whitley RJ et al. (1998) Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. Arch Intern Med 158: 957–969
Biron KK (2006) Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71: 154–163
Maguire PD et al. (1999) Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 45: 97–103
Choy H et al. (1999) Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 9: 90–96
Repici A et al. (2004) Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory benign esophageal strictures. Gastrointest Endosc 60: 513–519
Evrard S et al. (2004) Self-expanding plastic stents for benign esophageal lesions. Gastrointest Endosc 60: 894–900
Fuchs CS et al. (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21: 807–814
Raijman I et al. (1998) Palliation of malignant dysphagia and fistulae with coated expandable metal esophageal stents: experience with 101 patients. Gastrointest Endosc 48: 172–179
National Cancer Institute Common Toxicity Criteria [http://www.ctep.cancer.gov/forms/CTCAEv3.pdf/]
Sloan JA et al. (2002) Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20: 1491–1498
Cascinu S et al. (1997) Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. Support Care Cancer 5: 314–317
Abigerges D et al. (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210–221
Saltz LB et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905–914
Sargent DJ et al. (2001) Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 345: 144–145
Rothenberg ML et al. (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801–3807
Haller DG et al. (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26: 2118–2123
Kuebler JP et al. (2007) Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-Fluorouracil/Leucovorin plus or minus Oxaliplatin. Cancer 110: 1945–1950
Delaunoit T et al. (2004) Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer 101: 2170–2176
Perez-Soler R et al. (2004) Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 22: 3238–3247
Strumberg D et al. (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four Phase I trials in patients with advanced refractory solid tumors. Oncologist 12: 426–437
Lenz HJ et al. (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24: 4914–4921
O'Connell MJ et al. (1994) Improving adjuvant therapy for rectal cancer by combining protracted infusion-fluorouracil with radiation therapy after curative surgery. N Engl J Med 331: 502–507
Abigerges D et al. (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86: 446–449
Benson AB et al. (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22: 2918–2926
Wadler S et al. (1995) Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 13: 222–226
Barbounis V et al. (2001) Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9: 258–260
Kelly CP et al. (1994) Clostridium difficile colitis. N Engl J Med 330: 257–262
Anand A and Glatt AE (1993) Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 17: 109–113
Doern GV et al. (1992) Laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays. J Clin Microbiol 30: 2042–2046
Gerding DN et al. (1995) Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 16: 459–477
Knapp CC et al. (1993) Comparison of vidas Clostridium difficile toxin-A assay and premier C. difficile toxin-A assay to cytotoxin-B tissue culture assay for the detection of toxins of C. difficile. Diagn Microbiol Infect Dis 17: 7–12
Bartlett JG (2002) Antibiotic-associated diarrhea. N Engl J Med 346: 334–349
Apisarnthanarak A et al. (2002) Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 35: 690–696
Urbach DR and Rotstein OD (1999) Typhlitis. Can J Surg 42: 415–419
Tedesco FJ et al. (1985) Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 80: 867–868
Katz JA et al. (1990) Typhlitis. An 18-year experience and postmortem review. Cancer 65: 1041–1047
Gorschlüter M et al. (2005) Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 75: 1–13
Sloas MM et al. (1993) Typhlitis in children with cancer: a 30-year experience. Clin Infect Dis 17: 484–490
Wade DS et al. (1992) Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 69: 17–23
Kouroussis C et al. (2000) Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases. Am J Clin Oncol 23: 309–313
Shamberger RC et al. (1986) The medical and surgical management of typhlitis in children with acute nonlymphocytic (myelogenous) leukemia. Cancer 57: 603–609
Anderson H et al. (1987) VAD chemotherapy—toxicity and efficacy—in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol 5: 213–222
Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565–1571
Brandt LJ et al. (2005) Systematic review of the management of chronic constipation in North America. Am J Gastroenterol 100: S5–S21
Schwartz JM et al. (2001) Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes and outcome. Am J Gastroenterol 96: 385–393
Weisdorf DJ et al. (1990) Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 76: 624–629
Snover DC et al. (1985) A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 16: 387–392
Sviland L et al. (1988) Histologic features of skin and rectal biopsy specimens after autologous and allogeneic bone marrow transplantation. J Clin Pathol 41: 48–54
Cox GJ et al. (1994) Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 107: 1398–1407
Terdiman JP et al. (1996) The role of endoscopic evaluation in patients with suspected intestinal graft-versus-host disease after allogeneic bone-marrow transplantation. Endoscopy 28: 680–685
Daneshpouy M et al. (2002) Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood 99: 3033–3040
Carlens S et al. (1998) Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 22: 755
Atkinson K (1990) Chronic graft-versus-host disease. Bone Marrow Transplant 5: 69–82
Akpek G et al. (2003) Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant 9: 46–51
Shulman HM et al. (1988) A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 8: 463–470
Snover DC et al. (1984) Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 4: 123–130
Babb RR (1996) Radiation proctitis: a review. Am J Gastroenterol 91: 1309–1311
Keeffe EB et al. (2006) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4: 936–962
Stockdale AD and Biswas A (1997) Long-term control of radiation proctitis following treatment with sucralfate enemas. Br J Surg 84: 379
Sasai T et al. (1998) Treatment of chronic post-radiation proctitis with oral administration of sucralfate. Am J Gastroenterol 93: 1593–1595
Mayer R et al. (2001) Hyperbaric oxygen—an effective tool to treat radiation morbidity in prostate cancer. Radiother Oncol 61: 151–156
Al-Sabbagh R et al. (1996) Evaluation of short-chain fatty acid enemas: treatment of radiation proctitis. Am J Gastroenterol 91: 1814–1816
Biswal BM et al. (1995) Intrarectal formalin application, an effective treatment for grade III haemorrhagic radiation proctitis. Radiother Oncol 35: 212–215
Fantin AC et al. (1999) Argon beam coagulation for treatment of symptomatic radiation-induced proctitis. Gastrointest Endosc 49: 515–518
Tjandra JJ and Sengupta S (2001) Argon plasma coagulation is an effective treatment for refractory hemorrhagic radiation proctitis. Dis Colon Rectum 44: 1759–1765
Taieb S et al. (2001) Effective use of argon plasma coagulation in the treatment of severe radiation proctitis. Dis Colon Rectum 44: 1766–1771
Silva RA et al. (1999) Argon plasma coagulation therapy for hemorrhagic radiation proctosigmoiditis. Gastrointest Endosc 50: 221–224
Lucarotti ME et al. (1991) Surgical management of intestinal radiation injury. Dis Colon Rectum 34: 865–869
Lok AS et al. (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100: 182–188
Liang R et al. (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17: 394–398
Aksoy S et al. (2007) Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48: 1307–1312
Yeo W et al. (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62: 299–307
Yeo W et al. (2004) Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90: 1306–1311
Yeo W et al. (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22: 927–934
Kawatani T et al. (2001) Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 67: 45–50
Lee WM (1995) Drug induced hepatotoxicity. N Engl J Med 333: 1118–1127
Goldberg JW and Lidsky MD (1985) Cyclophosphamide-associated hepatotoxicity. South Med J 78: 222–223
George CB et al. (1984) Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer 54: 2360–2362
Moertel CG et al. (1993) Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 11: 2386–2390
Hohn D et al. (1989) A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7: 1646–1654
Kemeny N et al. (1987) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 107: 459–465
Chang AE et al. (1987) A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206: 685–693
Shorey J et al. (1968) Hepatotoxicity of mercaptopurine. Arch Intern Med 122: 54–58
Romagnuolo J et al. (1998) Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 12: 479–483
Berkowitz RS et al. (1986) Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 23: 111–118
Roenigk HH et al. (1982) Methotrexate guidelines: revised. J Am Acad Dermatol 6: 145–155
Johnson PJ et al. (1992) Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 65: 751–755
Fernandez FG et al. (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200: 845–853
Rubbia-Brandt L et al. (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15: 460–466
Vauthey JN et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24: 2065–2072
Hubert C et al. (2007) Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases. Liver Int 27: 938–943
Erichsen C and Jonsson PE (1984) Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. J Surg Oncol 27: 268–270
Stoneham S et al. (2003) Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 123: 100–102
Read AE et al. (1986) Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 104: 651–655
Sterneck M et al. (1991) Azathioprine hepatotoxicity after liver transplantation. Hepatology 14: 806–810
Rollins BJ (1986) Hepatic veno-occlusive disease. Am J Med 81: 297–306
Vassal G et al. (1990) Busulfan and veno-occlusive disease of the liver. Ann Intern Med 112: 881
Joensuu H et al. (1986) Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report. Cancer 58: 1437–1440
Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358: 2482–2494
Gordon MS and Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69: 25–33
Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342
Badgwell BD et al. (2008) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19: 577–582
Sugrue M et al. (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 24: 154s
Runzi M and Layer P (1996) Drug-associated pancreatitis: facts and fiction. Pancreas 13: 100–109
McArthur KE (1996) Review article: drug-induced pancreatitis. Aliment Pharmacol Ther 10: 23–28
Glueck CJ et al. (1994) Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemia women. J Lab Clin Med 123: 59–64
Hozumi Y et al. (1998) Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 83: 1633–1635
Kawanishi H et al. (1973) Azathioprine-induced acute pancreatitis. N Engl J Med 289: 357
Izraeli S et al. (1994) Acute pancreatitis after ifosfamide therapy. Cancer 74: 1627–1628
Mallory A and Kern F (1980) Drug-induced pancreatitis: a critical review. Gastroenterology 78: 813–820
Siemers RF et al. (1985) High-dose cytosine arabinoside-associated pancreatitis. Cancer 56: 1940–1942
Beaven AW and Shea TC (2007) The effect of palifermin on chemotherapy and radiation-induced mucositis:a review of the current literature. Support Cancer Ther 4: 188–197
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Davila, M., Bresalier, R. Gastrointestinal complications of oncologic therapy. Nat Rev Gastroenterol Hepatol 5, 682–696 (2008). https://doi.org/10.1038/ncpgasthep1277
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep1277
This article is cited by
-
Von Weinsäure zu Weinbeere – eine ungewöhnliche Form der Ösophagitis
Journal für Gastroenterologische und Hepatologische Erkrankungen (2023)
-
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice
Supportive Care in Cancer (2021)
-
Gut Microbiota as a Positive Potential Therapeutic Factor in Carcinogenesis: an Overview of Microbiota-Targeted Therapy
Journal of Gastrointestinal Cancer (2020)
-
Biliary and pancreatic complications of molecular targeted therapies in cancer imaging
Abdominal Radiology (2017)